INTRODUCTION
============

Living longer is one of the most remarkable human achievements over the past century. Successes in both preventive and curative medicine and widespread technological advances have resulted in a steady increase in life expectancy \[[@b1-jpmph-53-3-205]\], which in turn has led to worldwide population aging. The proportion of the elderly is expected to rise from 10% to 22% globally \[[@b2-jpmph-53-3-205],[@b3-jpmph-53-3-205]\]. Diseases and disabilities are considered to be significant challenges for the elderly \[[@b4-jpmph-53-3-205]\]. The medical expenses of seniors in the last 10 years have risen three-fold \[[@b5-jpmph-53-3-205]\]. The burden of disease in the elderly is associated with cardiovascular disease; malignant neoplasms; chronic respiratory conditions; diabetes; and joint, mental, neurological, infectious/parasitic, and cognitive diseases \[[@b6-jpmph-53-3-205]\].

Population aging influences the reimbursement system in healthcare. The elderly population drives demand for certain needs due to aging-associated diseases, and this issue poses challenges to the health sector \[[@b7-jpmph-53-3-205]\]. In most countries, the elderly are covered by medical and hospital services and pay lower out-of-pocket expenses for utilizing these services; however, meaningful differences among countries relate to the coverage of medications. The United States, for example, has implemented an insurance policy known as Medicare for the elderly \[[@b8-jpmph-53-3-205]\]. According to Chan et al. \[[@b9-jpmph-53-3-205]\], the costs of elderly patients in Singapore were more than expected. The financing schemes in Singapore reduced out-of-pocket payments by the elderly to some extent; however, financial support is particularly needed to compensate for out-of-pocket payments by ill elderly individuals who are not in good financial condition.

There is no standard numerical criterion mandated by the United Nations (UN), but the UN-agreed cut-off to refer to the older population is more than 60 years \[[@b10-jpmph-53-3-205]\]. According to the census conducted by the Statistical Center of Iran, it has been projected that the total population of Iran will reach 85 million by 2021, of whom approximately 10 million (8.5%) will be elderly. Given the increase in the prevalence of chronic diseases and the incidence of many disabilities among the elderly, healthcare for this group can impose heavy costs on these individuals, their families, and the health system (including insurance companies); this issue requires attention and timely planning. One reason for increasing healthcare expenditures is the increasing age of the population. Although policy-makers cannot stop population aging, it is important that they anticipate the health services needs of the elderly and the fiscal impacts of these demographic changes \[[@b11-jpmph-53-3-205]\].

Several studies, especially in European countries, have investigated the magnitude of the impact of aging on healthcare expenditures. Aging is one of the most significant drivers of health costs in the United States population, as the medical costs of the elderly are 3-5 times higher than those of younger people because of their increasing health needs \[[@b12-jpmph-53-3-205]\]. Brockmann \[[@b13-jpmph-53-3-205]\] showed that the costs of caring for people in their last year of life accounted for a higher percentage of health expenditures in Germany in 2002. Based on the understanding that aging leads to increased hospitalization costs, Hazra et al. \[[@b14-jpmph-53-3-205]\] analyzed healthcare costs in the senior elderly in the United Kingdom with the goal of addressing the empirical gap in the literature concerning the trajectory of healthcare costs in the over80s. The demographic transition has been considered as a major factor contributing to the costs of healthcare, although little attention has been paid to it. A possible reason for this is that identifying clear relationships among demographic changes, diseases, and costs is challenging. Therefore, we intended to conduct such an analysis for a hospital as a representative of the main type of institutional provider of healthcare.

Micro-costing analyses collect detailed data on resource utilization and the value of those utilized resources. Micro-costing analysis results can be presented as stand-alone studies or can be input directly into health economic evaluation analyses, such as cost-effectiveness analyses \[[@b15-jpmph-53-3-205]\]. Polder et al. \[[@b16-jpmph-53-3-205]\] showed that the healthcare costs in the last year of life were 13.5 times higher than the mean lifetime healthcare costs for a person, with costs of €14 906 in the last year of life. Furthermore, hospital care accounted for 54% of all these costs.

We, therefore, investigated hospital costs as a part of healthcare costs according to diagnosis, age, and sex to determine which illnesses and demographic categories in the elderly were associated with the greatest demands for hospital care. In light of the demographic changes that Iran will face in the future, this research is expected to be helpful for planning, allocating funds, and taking into account the needs of the elderly.

METHODS
=======

Data Source
-----------

Data were obtained from a teaching hospital using the Iranian hospital information system along with daily hospital admissions data. Hospital records were based on International Classification of Diseases, 10th revision codes. In order to prevent duplicate calculations, the final list of costs was considered. The selected hospital was a general hospital with 190 inpatient beds capable of accepting all types of patient admissions located in the center of Tehran, the capital city of Iran. This hospital was chosen based on availability and accessibility of the data.

### Study design

This was a retrospective, descriptive costing study. A bottom-up micro-costing analysis was performed in order to analyze the data.

### Sampling

The study was conducted among all elderly patients admitted to the hospital. All final bills in elderly patients' medical records from the fiscal year of 2017 were included. Therefore, no sampling was required. The data were registered in a designed form. Sex, age, Para clinical service costs, final status (recovery or death), cost of medications and drugs, and the type of inpatient ward were recorded.

### Costing analysis

A bottom-up approach was implemented. First, all cost items were identified. Second, all of the services provided to the elderly, such as surgical services, drugs, and medical tools, and paraclinical services (laboratory tests, magnetic resonance imaging, etc.) were considered. The elderly were divided into 6 age groups, starting at 60 years. The frequency, standard deviations, mean, minimum, and maximum costs were compared among the groups. Finally, we assessed the relationships between hospital inpatient costs and age, sex, type of disease, length of stay, ward, and final status. Furthermore, costs were categorized into 14 sections based on data in patients' medical records. All costs were converted into US dollars (US\$) using the exchange rate from 2017 (one US\$=42 000 rials) that was reported by the central bank of Iran.

Statistical Analysis
--------------------

Data were assessed for normality using the Kolmogorov--Smirnov test. Since this test showed data a non-normal distribution (*p*\<0.05), we used the Mann--Whitney test to evaluate the relationship between sex and costs and the Kruskal-Wallis test to evaluate the relationship between age group and costs. Stata version 13.0 (StataCorp., College Station, TX, USA) was used for the statistical analysis.

Ethics Statement
----------------

This study was approved by the AJA University in 2016 (registration code: 593191), but at that time studies that did not deal with the patient did not require ethical code.

RESULTS
=======

Of the 1288 elderly inpatients, 48.8% (n=629) were females, and their mean hospital stay was 7.7 days. The participants ranged in age from 60 years to 101 years, with a mean age of 72.63±8.68 years. The 60-64 years age group accounted for the highest percentage of patients (22.2%). Costs were classified into 14 items, as presented in [Table 1](#t1-jpmph-53-3-205){ref-type="table"}. Surgical operations, drugs and medical tools, and dialysis services had the highest average costs, of US\$294, US\$207, and US\$195, respectively. The mean cost per elderly patient was US\$637. The minimum and maximum hospitalization costs of the elderly patients in the hospital were \$21 and \$13 166, respectively ([Table 2](#t2-jpmph-53-3-205){ref-type="table"}).

In total, 22.4% of the total costs were accounted for by patients in the age group of 60-64 years, 17.5% by those in the age group of 65-69 years, 17.3% by those in the age group of 70-74 years, 19.7% by those in the age group of 75-79 years, 12.3% by those in the age group of 80-84 years, and 10.9% by those in the age group of 85 years and over. The highest and lowest proportions of total costs were accounted for by the age groups of 60-64 years and 85 years and over, respectively.

The Mann--Whitney test showed no statistically significant relationship between inpatient costs and sex (*p*=0.38), and the Kruskal-Wallis test showed no statistically significant relationship between the costs of hospitalization and age group (*p*=0.06). Death occurred in 39 cases (3.0%). The mean cost of these cases was US\$1768, which was 3.9 times higher than for patients discharged with partial recovery. A statistically significant relationship was observed between individuals' final status and inpatient costs (*p*\<0.001) ([Table 2](#t2-jpmph-53-3-205){ref-type="table"}).

The most frequent diseases were cancer and joint/orthopedic diseases, which accounted for 22.9% and 15.9% of cases, respectively. The mean cost per cancer patient was US\$409, and that for patients with joint/orthopedic conditions was US\$680. A statistically significant relationship was found between the type of disease and hospitalization costs, as well as a statistically significant association between the type of ward and hospitalization costs (*p*\<0.001). Patients with a length of stay of more than 10 days had higher mean costs (US\$1645) than those with shorter stays. There was a statistically significant relationship between the length of stay and inpatient costs (*p*\<0.001).

The surgical and internal medicine wards had the highest percentages of total costs (28.0% and 35.0%, respectively). However, the intensive care unit had the highest mean costs (US\$1387) ([Table 2](#t2-jpmph-53-3-205){ref-type="table"}).

DISCUSSION
==========

The presented data confirm that the costs of care were higher in patients facing death. The lowest overall proportion of hospitalization costs was found for patients who were 85 years of age and over. Nonetheless, this group had the highest average hospital costs, in line with previous studies such as that of Mcgrail et al. \[[@b17-jpmph-53-3-205]\], who showed an additional cost of dying even accounting for age-related increases in social and nursing costs. Polder et al. \[[@b16-jpmph-53-3-205]\] obtained a similar result in a study conducted in Denmark. In their study, the costs incurred by persons approaching death were 13.5 times higher than those of other individuals, and 54% of costs were associated with hospital care, whereas only 19% of them were related to nursing care at home. They showed that the highest costs were related to cancer, and the lowest costs were related to myocardial infarction \[[@b6-jpmph-53-3-205]\]. In our study, cancer and joint/orthopedic diseases accounted for the highest proportions of costs (22.9% and 15.9%, respectively), while joint/orthopedic diseases had the highest mean cost. This was mainly because patients with joint diseases spent more days in the hospital. Therefore, the results of our study do not match those reported by Polder et al. \[[@b16-jpmph-53-3-205]\].

Individuals approaching death utilized an increased amount of medical services, including medications. Kildemoes et al. \[[@b18-jpmph-53-3-205]\] investigated the effects of age on medication costs in Denmark. They considered current trends in medication use and estimates of medication use between 2003 and 2030. The increase in medication costs was estimated to be 16.9%, which was primarily accounted for by patients approaching death. In this regard, the findings of Kildemoes et al. \[[@b18-jpmph-53-3-205]\] agree with those of this study.

Aplin et al. \[[@b19-jpmph-53-3-205]\] studied the effects of patient-related variables on hospital costs. They collected data for 118 million hospital admissions from 2008 to 2010. Based on their results, length of stay, the number of procedures, major diagnostic categories, major operating room procedures, and ownership of the hospital were important variables affecting hospital costs. The results of our study are consistent with those findings. In our study, the type of disease (especially chronic conditions such as joint/orthopedic diseases), drugs, surgeons, and paraclinical services played important roles in hospital costs. Furthermore, the mean costs of the intensive care unit were higher than those of all other wards. Ziloochi et al. \[[@b3-jpmph-53-3-205]\] similarly reported that the intensive care unit had the highest costs, and that bed-days were associated with the highest cost share. The costs of caring for the elderly is a fundamental aspect that should be taken into account in the health sector, as these costs include outpatient and inpatient treatment, medications, diagnostic tests, and maintenance care at home or a nursing home for the elderly. Since the elderly receive a significant share of healthcare services, the costs of services provided to this stratum is of vital importance from a health economics perspective. The growth in the elderly population will cause challenges for the sustainability of the welfare and health systems.

Societies can take action to overcome these challenges, and by doing so they have the opportunity to increase the likelihood of high-quality life years and high-health status and to improve the efficiency of systems based on an appropriate consideration of the needs of the elderly. Population-based interventions will be critical for promoting health and avoiding diseases, as well as confronting aging. The public promotion of positive lifestyle steps such as avoiding smoking and consumption of alcohol, promoting physical activity, consuming a proper diet, and controlling obesity as part of active aging will not only lead to an increase in life expectancy and the postponement of costs, but also consequent economic benefits. As some studies have shown, integrating palliative and hospice care into the health system may be a highly effective intervention for cost-saving in hospitals \[[@b20-jpmph-53-3-205]\].

The limitations of the this study, we only studied elderly patients admitted to a single hospital in the city of Tehran, which may affect the generalizability of the results to the entire population. The studied hospital belongs to a military organization that mainly provides care for its members with low outof-pocket payments, which may pose problems for our initial assumption that there would be no induced demand or moral hazard.

The results showed that healthcare costs were higher for elderly patients approaching death, as the costs for patients who died were 3.9 times higher than those for persons discharged alive. For elderly people who suffer from chronic diseases, home care is recommended to reduce hospital costs.
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###### 

Mean expenditures for cost items for elderly hospitalized patients (US\$)

  Cost items                                                          Mean cost (%)
  ------------------------------------------------------------------- ---------------
  Visit^[1](#tfn1-jpmph-53-3-205){ref-type="table-fn"}^               8 (0.8)
  Consultations and nursing                                           41 (4.2)
  Surgical services^[2](#tfn2-jpmph-53-3-205){ref-type="table-fn"}^   294 (29.9)
  Drugs and medical tools                                             207 (21.1)
  Radiology                                                           8 (0.8)
  Sonography                                                          14 (1.4)
  Magnetic resonance imaging                                          41 (4.2)
  Computed tomography scans                                           21 (2.1)
  Laboratory and pathology                                            45 (4.6)
  Chemotherapy                                                        49 (5.0)
  Electromyography                                                    24 (2.4)
  Dialysis services                                                   195 (19.9)
  Rehabilitation                                                      8 (0.8)
  Nonsurgical services                                                27 (2.7)

US\$, US dollar.

Calculated per occupied bed-days.

Calculated for patients who underwent surgery.

###### 

Details on the costs of elderly hospitalized patients (US\$)

  Characteristic                                             Frequency (%)   Median   Mean   Min   Max      \% of total cost   *p*-value^[1](#tfn3-jpmph-53-3-205){ref-type="table-fn"}^
  ---------------------------------------------------------- --------------- -------- ------ ----- -------- ------------------ -----------------------------------------------------------
  Total                                                      1288 (100)      297      637    21    13 166   100                
  Sex                                                                                                                          0.380
   Female                                                    629 (48.8)      298      618    21    9815     47.0               
   Male                                                      659 (51.1)      297      655    27    13 166   53.0               
  Age (y)                                                                                                                      0.060
   60-64                                                     286 (22.2)      297      641    27    7887     22.4               
   65-69                                                     246 (19.1)      297      583    25    13 166   17.5               
   70-74                                                     235 (18.2)      299      603    33    10 007   17.3               
   75-79                                                     236 (18.3)      299      683    38    9815     19.7               
   80-84                                                     159 (12.3)      305      634    21    6789     12.3               
   ≥85                                                       126 (9.7)       296      710    33    10 398   10.9               
  Diseases^[2](#tfn4-jpmph-53-3-205){ref-type="table-fn"}^                                                                     \<0.001
   Blood and cardiovascular                                  129 (10.0)      326      579    51    3444     10.0               
   Cancer                                                    296 (22.9)      312      409    36    3051     18.0               
   Pulmonary and respiratory                                 26 (2.0)        308      365    39    709      1.0                
   Urogenital                                                77 (5.9)        308      406    55    4371     5.0                
   Joint and orthopedic                                      206 (15.9)      313      680    24    6626     22.0               
   Eye and ear                                               65 (5.0)        305      305    157   417      3.0                
   Digestive                                                 77 (5.9)        308      583    27    3444     7.0                
   Others                                                    412 (31.9)      307      561    26    10 231   34.0               
  Wards                                                                                                                        \<0.001
   Surgery                                                   361 (28.0)      307      691    31    8526     29.0               
   Internal medicine                                         451 (35.0)      305      548    37    6363     28.0               
   Hematology                                                309 (23.9)      305      470    33    3927     17.0               
   Intensive care unit                                       167 (12.9)      307      1387   57    13 166   26.0               
  Length of stay (d)                                                                                                           \<0.001
   1                                                         215 (16.7)      295      192    21    1015     5.0                
   2-5                                                       482 (37.4)      291      320    37    3927     19.0               
   6-10                                                      363 (28.2)      313      687    148   7887     30.0               
   ≥ 10                                                      228 (17.7)      326      1645   46    13 166   46.0               
  Final status                                                                                                                 \<0.001
   Recovery                                                  180 (13.9)      307      513    33    5292     13.0               
   Partial recovery                                          1056 (81.9)     307      454    17    8081     73.0               
   Death                                                     39 (3.0)        305      1768   44    10 231   13.0               
   Discharge against medical advice                          13 (1.0)        301      542    33    1152     1.0                

US\$, US dollar; Min, minimum; Max, maximum.

*p*-values are for mean costs.

The disease categories were based on International Classification of Diseases, 10th revision codes.
